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ABSTRACTIntravenous drug administration in Neonatal Intensive Care Unit is critical because of poor venous access, polymedication, fluid restriction, and low infusion rate. Since parenteral nutrition (PN) is infused intravenously, it is often considered as a vehicle for medication administration. Medications may be added to PN formulations in an effort to decrease fluid requirements, reduce the need for Y-site injections, reduce the possibility of line contamination due to manipulation, and decrease labor time required for drug administration. Risk is further increased by inadequate information on the physicochemical compatibility of drugs.
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INTRODUCTIONMalnutrition is a state in which a deficiency of nutrients such as energy, protein, vitamins and minerals causes measurable adverse effects on body composition, function or clinical outcome. Malnutrition is both a cause and a consequence of ill health. It is common and increases a patient’s vulnerability to disease. Methods to improve or maintain nutritional intake are known as nutrition support. These include oral nutrition support - for example, fortified food, additional snacks and/or sip feeds, enteral tube feeding - the delivery of a nutritionally complete feed directly into the gut via a tube and parenteral nutrition (PN) - the delivery of nutrition intravenously. These methods can improve outcomes, but decisions on the most effective and safe methods are complex [1].Ever since the late 1960s, when Wilmore and Dudrick first published their research on central venous alimentation, which promoted growth in an infant [2], PN has been an important adjunctive therapy for many patients with catabolic medical conditions including the elderly. Whether these patients are receiving this therapy in an acute-care setting, a long-term care setting, or at home, pharmacist should be knowledgeable about the therapy and be able to assess its effectiveness as well as prevent complications associated with total PN [3].Over the last four decades, PN has become an important primary (e.g., intestinal failure) and adjunctive therapy of disease states. PN is commonly used in such condition as severe pancreatitis, short-bowel syndrome, inflammatory bowel disease exacerbations, and gastrointestinal (GI) fistulae, as well as in critically ill patients, infants with very low birth weight, and patients with cancer receiving hematopoietic cell transplantation [4].
PN INPEDIATRICPN is used to treat children that cannot be fully fed by oral or enteral route, for example, due to severe intestinal failure [7]. Intestinal failure occurs when the GI tract is unable to ingest, digest and absorb sufficient macronutrients and/or water and electrolytes to maintain health and growth. Children differ from adults in that their food intake must provide sufficient nutrients not only for the maintenance of body tissues but also for growth. This is particularly true in infancy and during adolescence when children grow extremely rapidly. At these times, children are particularly sensitive to energy restriction because of high basal and anabolic requirements [8,9].
The ability to provide sufficient nutrients parenterally to sustain growth in infants and children suffering from intestinal failure or severe functional intestinal immaturity represents one of the most important therapeutic advances in pediatrics over the last three decades. Improvements in techniques for artificial nutritional support now ensure that children in whom digestion and absorption are inadequate or who are unable to eat normally no longer need to suffer from the serious consequences of malnutrition including death [10,11].
PN for newborn premature infantsPN is the intravenous (IV) infusion of all nutrients necessary for metabolic requirements and growth. PN refers to the IV infusion of nutrients by peripheral or central vein. Enteral nutrition (EN) is provided by oral or gavage feedings. PN is commonly indicated in neonates experiencing congenital malformation of the GI tract, gastroschisis, meconium and paralytic ileus, short-bowel syndrome, necrotizing enterocolitis, respiratory distress syndrome, extreme prematurity, sepsis, and malabsorption. The ability to provide EN and PN over the last four decades has significantly improved the overall survival of newborns when other options of adequate nutritional support were not possible [12].The goal of PN is to initially provide sufficient nutrients to prevent negative energy and nitrogen balance and essential fatty acid deficiency and support normal rates of intrauterine growth of appropriate composition without increased significant morbidity. Fear of toxicity and metabolic imbalance has alerted clinicians to use PN with caution, especially in the sickest and most premature infants. An increasing number of practitioners appreciate that this cautionary management has resulted in suboptimal nutrition intake of these infants. Practitioners have speculated that this cautionary practice contributed in part to national growth failure outcome statistics published of infants extremely low in birth weight (ELBW; <1000 g) and appropriate for gestational age (AGA; 
weight ≥10th percentile norm) born from 1995 to 1996. When assessed at 
discharge (≈36 weeks’ corrected age) 99% of these infants had significant growth failure with weights less than the 10th percentile compared with intrauterine growth standards [12,13]. Longer-term statistics indicate that a significant percentage of infants born very low in birth weight (VLBW; <1500 g) may suffer substantial neurodevelopmental deficits in part attributable to inadequate nutritional support in the neonatal period [14]. In more recent years, the earlier introduction and more aggressive advancement of PN were shown to be safe and effective, even in the smallest and most immature infants [15-19].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i2.15697
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Timely intervention with PN begins with the provision of glucose as soon as possible after birth with amino acids within the first 12 hrs, IV fat within the first 24-48 hrs, and trophic feeding within the first 24 hrs [20]. The optimal use of routine PN for nutritional support of  LBW and VLBW infants may influence short-term outcomes such as lower propensity to infection and shortened hospital stay, as well as longer-term outcomes such as decreased growth deficits, [56] improved neurodevelopment, and overall morbidity [21-23]. Indications that are generally recognized as those that necessitate PN for newborns are listed in Table 1.
Components of PN solutionsPN provides some or all nutrients of basal metabolism and growth for fluid, energy, macronutrients (protein, carbohydrate, and fat), and micronutrients (electrolytes, major minerals, trace minerals, and vitamins) [24-31]. Recommended intakes for premature and term neonatesare summarized in Table 2.An overview of fluid, macronutrient, and micronutrient recommendations follows.
FluidOn day one of life, maintenance fluids are met with a range between 80 and 140 mL/kg/d if the environment of the baby increases insensible water losses and 60-100 mL/kg/d in environments with increased humidity. Thereafter, fluid volume is advanced as tolerated to 120-180 mL/kg/d. Maximal fluid volume varies with individual management [25].
MacronutrientsCarbohydrate (dextrose) and fat (lipid emulsions) provide the energy needed to meet the demands of the circulatory, respiratory, neurological, and muscular systems, and when provided in adequate amounts, spare protein (amino acids) to support cell maturation, remodeling, growth, activity of enzymes, and transport proteins for all body organs. Energy needs may be increased with infection, chronic lung disease, healing, growth, and in babies who have experienced intrauterine growth restriction. Energy needs may be decreased with sedation, mechanical ventilation, and after tracheostomy placement.
Initiation and advancements of macronutrients in PN solutionsThe use of PN is suggested to support all ill and premature babies <1500 g that cannot sustain at least ~60 kcal/kg/denterally and initiation is recommended during the first 24 hrs of life to avoid excessive protein losses. The premature infant who is not growing, not septic, and not unduly stressed requires an energy intake of about 50 kcal/kg/d for 
resting energy expenditure, activity, and occasional cold stress [33-37], with as little as ~1-1.5 g protein/kg/d to preserve endogenous protein stores [17,38,39]. At least 60 kcal/kg/d is thought to meet energy requirements during acute sepsis [40]. Provision of >70 kcal/kg/d and 2.7-3.5 g protein/kg/d has been demonstrated to support growth and positive nitrogen balance in preterm infants [36].
Carbohydrate
Carbohydrate is delivered in 2.5-70% dextrose solutions that provide 3.4 kcal/g. Glucose is the energy source for all cells and is essential for the central nervous system, erythrocytes, and other tissues. To ensure a stressed premature infant receives an adequate but not excessive amount of glucose, the amount of carbohydrate delivered in the form of dextrose is commonly initiated at the endogenous hepatic glucose production and utilization rate of 4-6 mg/kg/minutes [41]; 8-10 mg/kg/minutes in ELBW infants provides 40-50 kcal/kg/d and preserves carbohydrate stores [32].Frequently smaller, more unstable premature infants develop hyperglycemia due to decreased insulin production and insulin resistance. Glucose infusion rates (GIRs) for these babies may need to be limited to 4 mg/kg/minutes or less, while larger preterm infants or term infants can often tolerate up to 8 mg/kg/minutes initially [34,42]. Once the GIR supports acceptable serum glucose values, it is advanced in a gradual, stepwise fashion (0.5-1 mg/kg/minute) to a suggested maximum glucose oxidative rate for neonates of 12-13 mg/kg/minutes to support growth and maintained there unless serum glucose values change significantly [43,44].
In most situations, a glucose concentration >12.5% is not necessary [34]. However, a higher glucose concentration may be needed when fluid intake is severely restricted or when the amounts of protein and/or fat are limited [34]. Excessive carbohydrate delivery above the amount that can be oxidized for energy and glycogen storage will lead to an increase in basal metabolic rate [45], fat deposition, cholestasis [46], hepatic steatosis [47], or overfeeding as described by the provision of energy in excess of needs for normal growth [47]. GIR >26 mg glucose/kg/minutes may contribute to infiltrates of fat in the liver [48].Practically, a premature infant who is able to tolerate a fluid volume of 140-150 mL/kg/d will meet macronutrient needs for growth if provided 
a dextrose concentration of 10% (~10-10.5 mg glucose/kg/minutes) or 
12.5% (~12-13 mg glucose/kg/minutes); if the protein and fat intakes are both at least 3 g/kg/d, the solutions will approximate 80-95 and 100-105 kcal/kg/d, respectively. Additional dextrose delivery from IV medication needs to be taken into account when calculating the GIR for individual babies [49,66].To optimize the amount of fluid available to provide nutrition to the small premature baby while trying to maintain a euglycemic state, it may be necessary to double-concentrate the continuous infusions that deliver medications and run them at lower rates. Consultation with the pharmacist can ensure that these lower medication infusion rates are the adequate for optimum clinical effectiveness of the IV drug. If further fluid restriction or dextrose limitation is necessary, other options to optimize the delivery of glucose are to minimize the amount of fluids delivered with IV medications or needed to keep a line patent and decrease the dextrose concentration of the IV medication solution so that slightly more dextrose can be delivered from the PN solution and/or increase the dextrose concentration of the IV medication solution to equal that of the PN solution while ensuring glucose tolerance [12].
ProteinProtein is delivered as free amino acids in solutions developed specifically for pediatric patients with an amino acid profile that is higher in amounts of amino acids believed to be conditionally essential for premature infants (aspartate, glutamate, taurine, and tyrosine) and with lesser amounts of glycine compared with adult solutions. Cysteine 
Table 1: Indications for PN support and route of administration 
for newborn infants who require intensive care
Route of PN 
administration
Indication for PN
Peripheral Temporary supply of nutrients<2 weeks:
↓2 Enteral intakeFunctional gut immaturityTemporary feeding intoleranceMedical instability
Central Prolonged nonuse of the (GI) tract>2 weeksShort-bowel syndromeSurgical GI disordersNecrotizing enterocolitisIntractable diarrheaMeconium ileusLine access in infants extremely lowIn birth weight<1000 gPN: Parenteral nutrition, GI: Gastrointestinal
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Table 2: Usual daily requirements of nutrients in PN solutions for preterm and term infants
Nutrient additive Usual daily requirements in PNNeonatal amino acid For maintenance:1.5-2.5 g/kg/dFor ELBW infants, begin at a minimum of 1.5 g/kg/d as Soon as possible.Goals for growth:3.5 g/kg/d for<1000 g3.0 g/kg/d for 1000-2500 g2.5 g/kg/d for>2500 g4.0 g/kg/d for some infants withgreater needsCysteine hydrochloride 40 mg/g of amino acids (120 mg/kg maximum)Refer to acetate guidelines for ELBW infants (see below under excess anions)Dextrose For maintenance:4-6 mg/kg/min (endogenous hepatic glucoseproduction)8-10 mg/kg/min (preserves carbohydrate stores)32Goals for growth: 12-13 mg/kg/minutesUsual maximum concentration:
12.5% peripheral route
20-25% central route
Lipid (20% emulsion from 100% soy oil) 0.5-4.0 g/kg/d; begin 0.5-1.0 g/kg/d and advance by 0.5-1.0 g/kg/dEssential fatty acids met with 1.0 g/kg/d and at least 80 kcal/kg/dDelivered as a component to the amino acid–glucose solution (admixture) or as a separate solutionEnergy Goals for maintenancePreterm/term: 60 kcal/kg/dGoals for growthPreterm: 90-110 kcal/kg/dTerm: 80-90 kcal/kg/d
Dextrose (40-60%), lipid (40-50%), protein (10-15%)Carnitine 2-10 mg/kg/d not to exceed 50 mg/kg/d69Heparin 1 unit/mL not to exceed 137 units/d0.5 unit/mL for ELBW infants when volume exceeds 150 mL/kg/dSodium (Na) as chloride or phosphate 2-4 mEq/kg/dPositive nitrogen balance is criticalfor growth; ELBW infants mayrequire increased intakePotassium (K) as chloride or phosphat 2-4 mEq/kg/dConsider omitting in ELBW infantsuntil renal sufficiency is wellestablishedChloride (Cl) 2-4 mEq/kg/dUsual Na: Cl is 1:1Excess anionsAcetateChloride Excess anion equivalent=(Na
+K)-(Cl+P)Usually provide electrolytes as acetate always use acetate if adding cysteine hydrochloride for ELBWCalcium (Ca) as gluconate 1-3 mEq/kg/d for maintenance3-4.5 mEq/kg/d for growth (see text for solubility limits)Should be administered through a central line rather than a peripheral line in premature infantsPhosphorus (P) as sodiumor potassium phosphate 1.3 mmol/kg/d for maintenance [29]1.5-2.0 mmol/kg/d for growthMagnesium (Mg) 0.25-1.0 mEq/kg/dBegin ELBW infants at low endIncreased needs for infants withostomy lossesVitamins as MVI-pediatric Premature: 2 ml/kg/day to a maximum of 5 mL/dTerm: 5 mL/dZinc (Zn) as sulfate or in PTE solution 400 µg/kg/d: Preterm infants and all infants with gastrointestinal losses250 µg/kg/d: Term infants 0-3 months100 µg/kg/d: Term infants>3 months and all infants with long-term PNCopper (as sulfate or in PTE) Withhold during the first 2 weeks of PN, then initiate at 20 µg/kg/dayDecrease amount or withhold with complication of obstructive jaundiceSelenium in PTE Withhold during the first 2 weeks of PNDecrease amount or withhold with complication of renal dysfunctionChromium in PTE Premature: Begin at 1.3 µg/kg/d and advance to 1.5-2.0 µg/kg/dTerm: 2.0 µg/kg/d
(Contd...)
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is also considered as conditionally essential in premature infants due to a theoretical insufficiency of enzymatic activity for the conversion of methionine to cysteine. Cysteine is not contained in amino acid solutions because of problems with long-term stability and addition as aseparate solution as the solution is prepared is compatible and is needed to meet recommendations [50]. Cysteine hydrochloride supplements may cause metabolic acidosis, and therefore, PN solutions may need to be buffered with acetate [12].Other special amino acid solutions designed specifically for patients with hepatic failure, renal disease, and higher protein needs have not been studied in infants and therefore are not recommended for infants. Amino acid profiles of these solutions are summarized elsewhere [51]. Amino acid solutions provide 4.0 kcal/g of protein. In neonates, protein accretion is thought to more adequately reflect nutritional status than weight gain [52]. Studies in preterm babies who receive PN suggest that protein accretion occurs by amino acid stimulation of protein synthesis rather than by suppression of protein break down [17,53].Protein requirements for the neonate tend to be inversely related to gestational age and size due to more rapid growth rates and greater protein losses in the smaller, more premature infants [54,55]. The early provision of protein is critical to attain positive nitrogen balance 
and accretion, as premature babies lose ~1% of their protein stores daily  [54,55]. The studies suggest the provision of at least 1 g/kg/d of amin acids can decrease catabolism [16,38,56]. ELBW infants can generally receive 2 g/kg/d of amino acids on the 1st day of life [16,57].A classic study by Zlotkin et al. [36] suggests a protein goal of at least 2.7-3.5 g/kg/d with the adequate energy of >70 nonprotein kcal/kg/d to approximate in utero nitrogen accretion. Studies show that early and aggressive provision of 3 g protein/kg/d and adequate nonprotein energy within the first few days of life is safe and effective at providing protein to meet accretion needs and facilitate intrauterine growth rates [15,34]. Protein requirements may be increased to counter catabolic or excretory losses in clinical conditions such as postoperative wound-healing, chronic lung disease treated with steroids, lymphatic injury with a sustained chyle leak, and/or during sustained periods when infants require limited or withheld enteral feeding or higher amounts of protein for catch-up growth [43,56-59].To date, there is no evidence from randomized trials to support the routine use of parenteral or enteral glutamine supplementation in preterm infants [59,60]. Studies in critically ill adults suggest that glutamine supplemented amino acid solutions may reduce mortality, improve nitrogen balance, and reduce the incidence of clinical infection [47].
FatFat is delivered as lipid emulsions of neutral triglycerides (TG), primarily polyunsaturated fatty acids (PUFAs) that are essential for normal growth and development, retinal development and function, brain development, and cell structure and function. Lipid emulsions provide a concentrated source of energy, 10 kcal/g of fat that enables the provision of nutrient intakes to premature infants within limited fluid volumes to achieve in utero rates of growth. Adequate administration of lipids prevents essential fatty acid deficiency, promotes positive nitrogen balance, and optimizes energy utilization. Solutions with 
100% soy oil provide 54% of energy as linoleic acid and 8% as linolenic 
acid, whereas the 50% soy and 50% safflower mixture provides 
66% of energy as linoleic acid and only 4.2% of energy as linolenic acid. Recommendations to prevent essential fatty acid deficiency in premature infants are to provide at least 80 kcal/kg/d, which will limit utilization of stored fat for energy and thus preserve docosahexaenoic acid and arachidonic acid stores [61,62]. An intake of linoleic acid is 
recommended at 4-5% of total calories and that of linolenic acid at 1% of total calories [61,63].Based on a minimal intake of 80 kcal/kg, a fat intake of 0.6-0.8 g fat/kg will meet linoleic acid recommendations and 1.0 g fat/kg will meet 
linolenic acid recommendations from a solution that is 100% soy. 
Because the 50% soy and 50% safflower mixture provides less linolenic acid, the amount required to meet recommendations is 2.0 g fat/kg. 
Lipid emulsions are available as 10 and 20% solutions; 20% solutions require less fluid volume and provide a lower phospholipid-to-TG ratio and therefore are recommended for premature infants. Lipid solutions also available with shorter chain and monounsaturated fats from olive oil and medium chain TG (MCT) oil. When compared with the longer chain TG solutions, those that contain MCT and olive oil provide a greater vitamin E to PUFA ratio, lower serum cholesterol, and are hydrolyzed more rapidly, but they may not be as effective in promoting protein accretion [64].
A 20% IV fat emulsion is typically started at 0.5-1 g fat/kg on the first day of life generally at the same time amino acids are started to prevent the occurrence of essential fatty acid deficiency as well as to provide a more generous source of calories. The lipid emulsion is advanced as tolerated in incremental rates of 0.5-1 g/kg/d to a typical maximum of 3 g/kg/d [48].
In a balanced PN solution, this generally approximates about 30% of total calories from fat. Fluid-restricted, growth-compromised patients or those limited to peripheral line access may require as high as 3.5-4 g fat/kg/d to achieve adequate energy for growth and protein 
Nutrient additive Usual daily requirements in PNManganese in PTE Withhold during the first 2 weeks of PNDecrease amount or withhold with complication of renal dysfunctionPremature: Begin at 0.05 µg/kg/d and advance to 0.05-0.2 µg/kg/dTerm: 0.2 µg/kg/dIodide (I) Withhold during the first 2 weeks of PNDecrease amount or withhold with complication of obstructive jaundiceMolybdenum (Mb) Premature: Begin at 0.75 µg/kg/d and advance to 1.0 µg/kg/dTerm: 1.0 µg/kg/dIron (Fe) as dextran or ferrous citrate Withhold for the first 3 months of PNPremature: 1.0 µg/kg/dWithhold for the first 3 months of PNDecrease amount or withhold with complication of renal dysfunctionFluoride (Fl) Premature/term: 0.25 µg/dMay withhold until 2 months of age (premature), 3 months of age (term) and consideredfor infants who do not receive regular blood transfusions.Premature/term: 1.0-2.0 µg/kg/dWithhold for the first 3 months of PN then provide premature with 500 µg/kg/dSolutions may be contaminated with fluoridePN: Parenteral nutrition, PTE: Pediatric trace element, MVI: Multivitamin for infusion, ELBW: Extremely low in birth weight
Table 2: (Continued)
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sparing. This intake is appropriate as long as the fat intake remains 
<60% of nonprotein calories. In neonates, the maximal removal capacity of plasma lipids was shown to be 0.3 g/kg/hr. To minimize the occurrence of hyperlipemia, bilirubin displacement, and respiratory 
compromise, lipid infusion rates ≤0.15 g/kg/hrs are recommended 
to span over 24 hrs. The delivery of 3 g/kg/d of a 20% lipid emulsion equates to an infusion rate of 0.125 g/kg/hr [48,65].Premature infants have limited fat stores and lipoprotein lipase concentrations that may hinder their ability to clear plasma lipids following infusions of IV fat [15]. The use of heparin dosing at 0.5-1 units/mL of total parenteral nutrition solutions, with a maximum of 137 units/d, can facilitate lipoprotein lipase activity to help stabilize serum TG values [43,64].Lipids may be restricted in patients with hyperbilirubinemia in minimum amounts that will provide only the essential fatty acids. Some clinicians will reduce or withhold lipids if rising bilirubin trends approach levels requiring exchange transfusions. Because both lipids and bilirubin are transported in the blood by albumin, lipids competing for binding sites on albumin may result in insufficient binding of bilirubin to facilitate excretion [49]. Persistently, high bilirubin values may increase the risk of kernicterus from the deposition of bilirubin in brain cells. A free fatty acid to albumin ratio (FFA: Albumin) >6:1 is thought to be clinically significant [57,67].
Micronutrients
ElectrolytesSodium, potassium, and chloride are essential to life and requirements are dependent on obligatory losses, abnormal losses, and amounts necessary for growth. Estimated and advisable intakes are based on accretion studies and urinary and fecal losses from balance studies completed in the late 1970s [26]. Sodium and potassium can be given as chloride, lactate, or phosphate salts. Infants who receive electrolytes solely as chloride salts may develop hyperchloremic metabolic acidosis. Sodium can also be given as acetate; a randomized trial in 1997 demonstrated the utility of acetate in PN solutions [27]. Potassium is added when the urinary flow is established and sodium is added post-diuresis. Chloride is generally given as sodium chloride. Thorough and up-to-date discussions of fluid and electrolyte management of premature infants are published elsewhere [26,28].
Major mineralsCalcium, phosphorus, and magnesium are the most abundant minerals in the body. They are closely interrelated to each other in metabolism, the formation of tissue structure, and function. Amounts of calcium 
and phosphorus are initiated at maintenance levels and advanced when energy and protein intakes are adequate to support intrauterine accretion rates of lean tissue [29]. The adequacy of these nutrients from PN solutions has been studied extensively in the premature population and in-depth discussions appear elsewhere [30,31,68-72].
Trace mineralsRecommended amounts for trace minerals are listed in Table 3. The 1988 American Society of Clinical Nutrition (ASCN) guidelines [73] are given for term and preterm infants and compared with the 1993 consensus recommendations of an international panel of experts for preterm infants that are defined as transitional (within the first 2 weeks’ of life) and stable (after 2 weeks’ of age) [74]. Zincis universally recommended from day one of PN, whereas the other trace minerals are generally provided after 2, 4, or 12 weeks’ of PN without any appreciable enteral feeding. Copper, selenium, molybdenum, and iron can be delivered separately also. Several trace element solutions are available with varying combinations of zinc, copper, chromium, manganese, and/or selenium [31]. Copper and manganese are discontinued from PN solutions with the complication of cholestasis, and amounts of chromium, selenium, and molybdenum are reduced or omitted when renal output is low [73]. Many of the component solutions to PN are found to be “contaminated” with trace elements, and therefore, administration before actual need may increase risk for toxicity [52,75-78]. Some have suggested copper requirements greater than the 20 µg/kg/d recommendation [30,73,74,79].Because of the oxidant effect of copper as well as the risk of toxicity from limited excretion in patients with cholestasis, Greene et al. [73] advise the lower amount. Minimal enteral feedings are also a source of copper within the first 2 weeks. Although they may cause allergic reactions, iron dextran and ferrous citrate can be used to supplement PN solutions. Parenteral iron supplementation may be delayed until 2 months of age in premature infants and 3 months of age in term infants and considered for those infants who do not receive regular blood transfusions [31]. Concern for iron overload is related to increased risk for septicemia in malnourished infants with a low serum transferrin as well as an increased need for vitamin E [31,73,80]. Even though recommendations for premature infants exist within the first 2 weeks of life for copper, selenium, chromium, iron, iodide, and manganese, these trace minerals generally are not added to PN but are provided within minimal enteral feedings. Supplementation with iodide may not be necessary because needs for iodide may be met from the topical absorption of iodide-containing disinfectants, detergents, and other environmental sources [73].
Table 3: Amounts of trace minerals recommended for term and preterm infants in PNa
Trace 
elements
Term (µg/kg/d) Preterm (µg/kg/d) ASCN (1998)
Consensus recommendations (1993)
ASCN (1988) Transitional (first 2 weeks of life) Stable (>2 weeks old)ChromiumbCopperc, d 0.20 0-0.05 0.05-0.2 0.2Irone 20 0-20 20 20Flouridef - 0-200 100-200 -Iodide - - -Manganesec 1.0 1.0 1.0 1.0Molybdenumb 1.0 0-0.75 1.0 1.0Seleniumb 0.25 0 0.25 0.25Zincg 2.0 0-1.3 1.5-2.0 2.0250 150 400 400aReprinted with permission from Denne et al. [34] Recommendations are those from the ASCN, subcommittee on pediatric PN requirements, from the Committee on Clinical Practice Issues, 1988, 25 and Greene et al. [74]. bRenal dysfunction can cause toxicity. cImpaired biliary excretion can cause toxicity. dGreater amount (40 µg/kg/d) is suggested for very low in birth weight infants without cholestasis. eEstimated daily IV requirement is 100 µg/kg for term infants and 200 µg/kg for preterm infants. fOnly consider with PN longer than 3 months as solutions may be contaminated with fluoride; a dosage of 500 µg/kg/day for preterm infants. gThe only trace element recommended on day 1 of TPN. When TPN is required_3 months, decrease dosage to 100 µg/kg/d. PN: Parenteral nutrition, ASCN: American Society of Clinical Nutrition
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VitaminsThe most recent guidelines for parenteral vitamin administration for infants remain those published as the consensus recommendations from an international panel of experts in 1993 [74]. These are compared in Table 4 to those recommended in 1988 by the ASCN [73]. For the most part, recommended intakes are based on serum vitamin concentrations measured in term and preterm infants who received various amounts of different vitamins [73]. These studies were primarily completed in infants >1000 g at birth. Thus, specific needs of ELBW infants remain unclear [81]. There commended parenteral vitamin intakes can only be approximately delivered from multivitamin for infusion (MVI) pediatric. The standard dose of 2 mL/kg/d with a maximum intake of 5 mL/d provides lower amounts of vitamin A and higher amounts of most of the B vitamins (Table 4). Furthermore, IV vitamin delivery may be less due to photodegradation of vitamins A, D, E, K, B2, B6, B12, C, and folic acid and adsorption of vitamins A, D, and E into the vinyl delivery bags and tubing [43]. Some clinicians have addressed these issues with the protection of delivery equipment from light and the administration of fat-soluble vitamins with lipid [82,83]. The need for a newly formulated pediatric MVI solution that better meets the premature infant’s needs has been discussed and recommendations for its composition have been suggested [30,73].
COMPLICATIONS ASSOCIATED WITH PNComplications associated with PN therapy can be categorized into mechanical, metabolic, and infectious problems. The pharmacist must be aware of these complications and how they are likely to present, when they are likely to occur, and what can be done to prevent them.
MechanicalMechanical complications are catheter-related and may occur short- or long-term. Short-term complications are those related to catheter insertion and include pneumothorax, hemothorax, subclavian artery injury, air embolism, thoracic duct injury, catheter embolization, and catheter malposition [84].Long-term mechanical complications include catheter occlusion, thrombosis, and catheter breakage. Catheter occlusion is the most frequent noninfectious mechanical complication seen with the use of long-term venous access devices. It may be due to a blood clot, fibrin 
sheath, drug or calcium precipitate, or catheter pinch-off syndrome. Occlusion can be prevented by correct catheter position, a routine flushing protocol with heparinized saline, monitoring of drug and nutrient incompatibilities, and use of in-line filters [85].Thrombosis development can be promoted by catheter malposition or injury to the vein wall during or after catheter insertion, or it can be chemically induced. The catheter tip should be positioned at the junction of the superior vena cava and the right atrium. Venous thrombosis can be manifested by neck or arm swelling or pain. Treatment depends on the extent of the thrombus, the need to maintain current access, and the severity of symptoms. The conservative approach is to leave the catheter in place and to give anticoagulation therapy. Catheter removal may be warranted with extended thrombus [86,94].
MetabolicMetabolic complications are clearly the problem area, in which pharmacists can have the most input into prevention and treatment. These complications can be categorized as short- and long-term issues. In the hospitalized patient, PN is usually infused over 24 hrs, and as the patient is transitioning to home or long-term care, the PN solution is cycled (given over a shorter period of time such as 6-12 hrs). Usually, the infusion rate is increased over the first several hours and decreased (tapered) over the last hours of the infusion period. This will help temper some of the short-term metabolic complications that are described below. Short-term complications include refeeding syndrome, hyperglycemia and hypoglycemia, mineral and electrolyte imbalances, and hypertriglyceridemia. Most of these can be prevented with careful monitoring, proper nutrient dosing, and conformation to standard PN labeling guidelines [92].Refeeding syndrome is one of the most critical complications that occur with the initiation of PN. It has been elegantly described by Solomon and Kirby [87] and is defined as the metabolic and physiologic consequences of the depletion, repletion, compartmental shifts, and interrelationships of phosphorus, potassium, magnesium, glucose metabolism, vitamin deficiency, and fluid resuscitation. More specifically, as an extremely malnourished individual is started on PN, cardiopulmonary and neurologic complications may occur as a result of hypokalemia, hypophosphatemia, and hypomagnesemia among 
Table 4: Amounts of vitamins recommended for term and preterm infants in PN solutions compared to prescribed dosages of 
MVI‑pediatrica
Vitamin Term (dose/d) Preterm (dose/kg/d)
ASCN (1988) MVI‑pediatric 
(1 vial; 5 ml)
Consensus 
recommendations (1993)
ASCN (1988) MVI‑pediatric 
(40% of vial; 2 ml/kg/d)bFat solubleVitamin A (IU) 2300 2300 700-1500 1640 920With lung disease - - 1500-2800 - -Vitamin D (IU) 400 400 40-160 160 160Vitamin E (IU) 7.0 7.0 3.5 (max=7) 2.8 2.8Vitamin K (µg) 200c 200c 6-30 (at birth) 80 80Water solubleVitamin B6 (µg) 1000 1000 150-200 180 400Vitamin B12 (µg) 1.0 1.0 0.3 0.3 0.4Vitamin C (mg) 80 80 15-25 25 32Biotin (µg) 20 20 5-8 6.0 8.0Folic acid (µg) 140 140 56 56 56Niacin (mg) 17 17 4.0-6.8 6.8 6.8Pantothenate (mg) 5.0 5.0 1-2 3.0 2.0Riboflavin (µg) 1400 1400 150-200 150 560Thiamin (µg) 1200 1200 200-350 350 480aReprinted with permission from Denne et al. [34]. Recommendations are those from the American Society of Clinical Nutrition (ASCN), Subcommittee on Pediatric PN Requirements, from the Committee on Clinical Practice Issues, 1988, [73] and Greene et al. [74]. Needs of the Preterm Infant: Scientific Basis and Practical 
Guidelines. Baltimore, Williams These recommendations are currently not achievable because no ideal IV vitamin preparation is available for preterm infants; 40% of a vial (2 ml/kg/d) of MVI-pediatric (Armor, USA, Rover, Canada) is the closest intake that can be achieved at this time. bMaximum not to exceed a dosage of 5 ml/d. cThis does not include the 0.5-1.0 mg of vitamin K given at birth, as recommended by the American Academy of Pediatrics [48]. PN: Parenteral nutrition, ASCN: American Society of Clinical Nutrition, MVI: Multivitamin for infusion
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other reasons. Risk factors for refeeding include alcoholism, anorexia nervosa, marasmus, rapid refeeding, and excessive dextrose infusion. The prevention of refeeding syndrome includes repletion of potassium, phosphorus, and magnesium; limiting dextrose dosing initially; limiting sodium in early PN solutions [95].Hyperglycemia is the most common metabolic complication associated with PN. Risk factors include metabolic stress, concurrent glucocorticoid therapy, diabetes, obesity, sepsis, and excessive dosage of glucose. The prevention includes limiting glucose administration to 2-3 mg/kg/minutes for at-risk patients, and 5 mg/kg/minutes in others, along with monitoring glucose every 6-8 hrs. The treatment includes decreasing the glucose dosage, administering regular insulin to keep glucose levels from 150 to 200 mg/dl, or both [89,96].Hypoglycemia occurs most often when PN is suddenly discontinued. This can happen with occlusion of the central venous catheter, malfunction of the IV pump, or cycling off the PN. It can be prevented by slowly tapering the infusion rate and monitoring blood glucose concentration 1-2 hrs after the PN is discontinued [97].Mineral and electrolyte imbalances include elevated or deficient levels of sodium, potassium, calcium, magnesium, phosphorus, or chloride. The most common imbalances that occur with PN are hyponatremia resulting an excess of hypotonic fluid, hypokalemia resulting from inadequate potassium intake, intracellular shifts or excessive GI losses, hypophosphatemia resulting from inadequate phosphorus intake or intracellular shifts, and hypomagnesemia resulting from alcoholism and refeeding syndrome. These imbalances can be prevented by providing an adequate dose of minerals and electrolytes as suggested in the ASPEN safe practices report and providing recommended volume requirements of 20-40 ml/kg/day to prevent fluid overload or dehydration [92]. The treatment for these imbalances includes assessing excess losses and repleting minerals and electrolytes in the PN solution when possible (calcium-phosphorus compatibility limitations may prevent full repletion via the PN solution) [5].Hypertriglyceridemia may occur in patients who are unable to metabolize the IV lipids. Patients with baseline hypertriglyceridemia such as those with sepsis, AIDS, or lipid-induced acute pancreatitis may need to have lipid-free or low-dose-lipid PN. Monitoring of the TG level elevation over baseline after a low dose of lipids will help gauge whether patients must have lipid-free PN or whether a daily, continuous, low-dose infusion can be tolerated [90].Long-term metabolic complications include hepatic dysfunction, metabolic bone disease, and trace element deficiencies. Hepatic dysfunction associated with PN is considered to be of a multifactorial nature. Causes include infusion of carbohydrates at an excess of 5 mg/kg/minutes and sepsis. Steatosis occurs and can cause an elevation of transaminases and alkaline phosphatase days to weeks after initiation of PN. Elevated bilirubin concentration is seen less often, and enzymes lost often return to normal after the PN is discontinued. Treatment options include giving at least one-third of calories as lipids, cycling PN over 12 hrs to decrease continuously elevated insulin levels, and using the GI tract to stimulate bile flow [91,98].Metabolic bone disease is a well-documented complication of long-term PN therapy. It may demonstrate itself as back pain, periarticular bone pain, or fracture. Adults may exhibit hypercalcuria due to excessive infusion of fluid, sodium, magnesium, phosphate, vitamin D, or amino acids [99].Trace element deficiencies may occur in patients receiving long-term PN. Periodic zinc, chromium, iron, copper, and selenium levels should be measured, and these trace elements repleted as necessary [100].
InfectiousInfectious complications can occur anytime during the course of PN therapy. The two general sources of these complications are catheter-related infection and solution-infusate contamination. The risk of 
catheter-related bloodstream infection remains one of the most serious complications associated with PN [101]. Temporary or short-term 
central venous catheters account for about 90% of nosocomial blood 
stream infections, and only 10% of infections are from long-term devices such as tunneled catheters or implanted reservoirs [102].
Risk factors for catheter-related infection include age ≥60 years, increased severity of illness, distant site of infection, skill of inserter, use of catheter, and site of catheter placement [103]. The patients can also develop local site infections, port pocket infections, or catheter tunnel infections without developing a full blood stream infection. Signs and symptoms associated with catheter-related sepsis include fever, rigors, malaise, defervescence of fever after catheter removal, and positive blood cultures [102]. Treatment options include catheter removal, antibiotic lock, or delivery of systematic antibiotics via the catheter [93]. The prevention of a catheter-related infection can be aided by trained personnel with the use of aseptic technique in catheter placement and routine site care, flushing protocols, and tubing changes. Clinical monitoring for catheter-related infections includes assessing the patient’s temperature, complete blood cell count with differential count, blood glucose level (sudden hyperglycemia may be an early warning sign), and the catheter insertion site [103].
COMPATIBILITY OF PNThe patients receiving PN therapy often required concomitant drug therapy. Most patients have adequate venous access or have multiple lumen central venous catheters so that mixing medications with the PN formulation is not that issue. However, for some patients with limited venous access, directly added medications or piggybacking medication via a secondary infusion must be considered. The compatibility of these medications and other IV solutions is an important concern in delivering safe and effective drug and nutritional therapy. IV medications are infused most often as separate admixture piggybacked in the PN line. However, some medications may be added directly to PN solution and administered at the same rate as the PN infusions. Because of the potential for ineffective drug therapy or other complication associated with physiochemical incompatibility and stability of the PN solution, specific criteria should be considered before one add a medication directly to PN solution [107].Since PN is infused intravenously, it is often considered as a vehicle for medication administration. Medication may be added to PN formulations in an effort to decrease fluid requirements, reduce the need for Y-site injections, reduce the possibility of line contamination due to manipulation and decrease labor time required for drug administration. Although these reasons may seem compelling, the physicochemical complexity of PN formulations makes their interactions with parenteral medications a very challenging compatibility dilemma [6].The stability and compatibility of total PN mixtures compounded for patients requiring nutritional support is paramount to their safety on IV infusion. The most significant pharmaceutical issues associated with mixing total PN formulations affecting their safety involve the stability of lipid-injectable emulsions and the compatibility of calcium and phosphate salts [99].Drug-nutrient interactions result in derangements in fluid and electrolyte homeostasis, changes in vitamin status, and disturbances acid-base balance. Recognition of these drug-nutrient interactions may assist the clinician to prevent metabolic complications and to achieve desired therapeutics outcomes [99,100]. A major disadvantage to the use of PN solutions as drug delivery vehicles is the lack of compatibility and stability data in the PN solutions that are used commonly in clinical practice.
PN and drug therapyPatients requiring PN suffer from severe functional or anatomical failure of the gastrointestinal tract. The decreased intestinal absorption affects the fate of xenobiotics like drugs leading to erratic or absent 
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bioavailability. To overcome the lack of IV access and to reduce complicated drug treatments the use of a PN admixture as a vehicle for drug treatment is attractive. However, admixing of a solubilized drug to an All-in-one (AIO) PN must meet good manufacturing practice to avoid microbial contamination, to guarantee a defined formulation, and to prevent medication errors. It should be also kept in mind that the admixing of a drug to PN creates a new formulation with changed properties. This may eventually affect both the bioavailability of the PN and of the drug. The literature background is sparse. The variety of PN regimens and of drug dosages is huge. Therefore, pharmaceutical expertise is mandatory for safe and effective treatment [88,101,102].
Incompatibilities and interactionsIncompatibilities include physicochemical reactions occurring in vitro. Pharmacological interactions take place in vivo and affect drug action (synergy or antagonism, adverse drug reactions). AIO mixtures constitute the standard for PN; in the ready to use form they show restricted stability and shelf life. The high number of chemically reactive components and the oil/water (o/w) emulsion character of lipid-containing AIO admixtures represent a most complex vehicle for drug admixing [102]. Incompatibilities may result from direct reactions between soluble components but also from reactions with the container material or with the gas (oxygen) present in the container. These physicochemical reactions depend on concentration, temperature, and other co-factors such as light exposure and catalysts (trace elements) [97,104,105]. When drugs are added via a Y-site infusion or injection, or by a three-way-stopcock, except for the exposure time (time-dependent reactions), there is no general difference regarding incompatibility reactions in this situation (Table 5) [106].The following aspects of drug admixing to feeds will be considered (Fig. 1) [106]:
• Changes of the emulsion character of the PN formulation
• Reaction of the drug formulation with the AIO bag material (ethyl 
vinyl acetate [EVA], polyvinyl chloride [PVC], polyolefin, etc.)
• Reactions with specific nutrients leading to inactivation (oxidation, etc.)
• Reactions with components leading to toxicity (e.g., precipitation, radical formation).
Emulsion changesThe o/w emulsion of an AIO admixture is stabilized by amphiphilic phospholipid emulsifier (lecithin). Stability is also dependent on the source of the TGs, the amino acid pattern, the glucose content (viscosity), the electrolyte and trace element concentration, and the pH. In a pH range of 5-8, the negatively charged phosphate moiety of the emulsifier prevents coalescence of the small oil droplets (250-500 nm diameter) by electric repulsion [101].However, this zeta potential is decreased by (polyvalent) cationic agents including positively charged drugs (aminoglycosides) or divalent cationic drug salts (Ca- or Mg heparin). Reduced repulsion forces between the oil droplets eventually lead to irreversible creaming and oiling out [1,102,104].Therefore, drug formulations with a low pH (e.g., midazolam and vancomycin) or a very high pH (aciclovir, furosemide, metoclopramide, phenytoin, barbiturates, etc.) should not be admixed to lipid-containing AIO admixtures without emulsion dispersal testing, e.g., by light microscopy. Highly lipophilic drugs (log Poctanol _3) dissolved as micelles by amphiphilic solvents like cremophors or tweens may also interact with the lipid emulsion. The resulting formulation, even when showing increased o/w emulsion stability, may change the biodisposition of the drug and of the TGs (FFA release). Similar reactions may occur with other lipophilic drugs like paclitaxel or amphotericin B showing small therapeutic indices too. The same has to be considered for liposomal formulations. Such drug admixing should be omitted in the absence of documented effectiveness and safety of the treatment [103,106].
Incompatibilities with the bag materialFor lipid containing AIO admixtures plastic bag material without softeners is mandatory because of their potential extraction by lipids, e.g., phthalates from PVC. EVA and polyolefins (multi-layered foils) are common container materials without softeners. Significant amounts of lipophilic drugs – such as diazepam, nitroglycerine, and dihydropyridines - may be absorbed into (PVC) plastic material. Protein drugs - such as albumin, insulin, and growth factors - may also be adsorbed on the container surface. Therefore, such drugs should not be added to large volume parenteral feeds to avoid loss of active drug [104,106].
Inactivation of drugs or PN componentsPN is not an inert vehicle but contains essential nutrients intended to be administered unchanged. The organic nutrients contain aldehyde-, OH- or amino-groups (glucose, amino acids) or conjugated double bonds (PUFA) prone to chemical reaction with corresponding compounds. Such drugs are characterized by reduced stability and a high incompatibility profile (e.g., catecholamines). Most short acting medications, used especially in Intensive Care Unit, show high chemical reactivity. They should not be added to AIO admixtures due to potential rapid inactivation [102].The presence of trace elements such as iron, copper, and selenium may even catalyze oxidative or reductive degradation of drugs (epinephrine) or nutrients (ascorbic acid). Such reactions are only partly accompanied by color changes of the solution (Maillard reaction) and are not always detectable by visual inspection. In contrast, ultraviolet spectrophotometry may be able to assess such drug inactivation because of the specific absorption analysis of the respective compound. Chelators included in drug dosage forms for stability reasons may interfere with trace element or electrolyte availability (e.g., EDTA in propofol formulations) [102,107].
Fig. 1: Incompatibility reactions in parenteral nutrition
Table 5: Incompatibility reactions
Chemical reactions Physical reactionsOxidation/Reduction (catecholamines) Precipitation (solubility) (midazolam pH>5)Hydrolysis (beta-lactam antibiotics) Sorption (diazepam and PVC)Polymerization, condensation Permeation (iodine)(Maillard products)Permeation (iodine)Cleaving reactions (prostaglandins) Destabilization of disperse systems(e.g., emulsion)Racemate formation (L-n-epinephrine) Thermal reactionsEpimerization (tetracyclines)Complex formation (Ca þ quinolones)PVC: Polyvinyl chloride
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Degradation reactions leading to potential activityThe solubility of drugs very much depends on the pH of the solution because of the acid/base character of most drugs (pKa). Variation in pH among different producers of the same drug may also be relevant and make extrapolation difficult. Weak acids or weak bases need high or low pH to form water-soluble salts. When added to a buffered AIO admixture, precipitates are formed reducing the drug and/or nutrient concentration according the solubility product. Local pH differences may even be more pronounced with Y-site or three-way-stopcock administration. Precipitates may be harmful or even fatal. An in-line filter is not always a guarantee of preventing precipitates being infused. As an example, Ca phosphate precipitate is formed when the solubility product is exceeded. The salt is more soluble in the cold and may therefore only precipitate if the PN admixture is warmed up. In contrast to binary PN admixtures, lipid-containing AIO admixtures cannot be assessed visually and filters of 1.2 mm pore size used for lipid emulsion do not eliminate small particles. Therefore, drugs dissolved at pH <5 or >7 (alkaloids, virostatic drugs, vancomycin, etc.) are a problem in PN admixtures. Lipid peroxidation of PUFA results in radical formation, which can be harmful to the patient. Drugs sensitive to oxidation/reduction processes may react with PUFA or radicals and modulate peroxidation chain reactions. Molecules like tricyclic phenothiazenes (chlorpromazine) easily interact with such electron transfer processes and are therefore unsuitable for AIO admixing [103,107].
Practical guidelines for drug therapy [103,104,106,107]
• Patients with PN should have a multi-lumen catheter for medication therapy
• AIO admixtures represent a most complex and reactive vehicle for drug admixing not suitable for most drugs (incompatibilities)
• Intermittent IV administration with sufficient rinsing fluid has to be preferred to admixing whenever possible
• Pharmaceutical advice from the nutrition team has to be respected in every situation where therapeutic drug admixing is necessary
• Physicochemical characterization of the drug formulation is a prerequisite to estimate possible compatibility (pH, pKa, physicochemical stability of the active ingredient, formulation additives, etc.)
• Molar concentration ratios between reaction partners have to be considered
• Admixing is possible only immediately before administration at maximal dilution
• Check the therapeutic effect of the admixed drug as an indirect bioavailability test
• The use of standard PN formulations and standard drug protocols will allow the establishment of a data base for reference.No admixing when:
• Presence of solubilizers to dissolve lipophilic drugs (ethanol, cremophor, etc.)
• Drugs with chemical instabilities (lyophilisates)
• Small therapeutic indices of the drug (cytotoxics, etc.)
• Short elimination half-lives of the drug (limited variation in administration speed).Admixing possible when:
• Sufficient stability reported (literature, experimental analysis)
• Drug formulation compatible with pH of AIO admixture
• No ingredients with incompatibilities with AIO admixtures (divalent cations)
• Large therapeutic index of the drugs involved (analgesics, sedatives, H2-antagonists)
• Aseptic admixing and documented protocol given (pharmacy with controlled areas)
• Simple stability testing possible (pH, lipid droplet size analysis, inspection for coloration and precipitation)
• In-line filter.
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